You should read the following discussion and analysis of our financial condition
and results of operations together with our consolidated financial statements
and accompanying notes that are included elsewhere in this Annual Report on Form
10-K. This discussion contains forward-looking statements based upon current
expectations that involve risks and uncertainties, as described under the
heading "Special Note About Forward-Looking Statements" in this Annual Report on
Form 10-K. Our actual results may differ materially from those anticipated in
these forward-looking statements as a result of various factors, including those
set forth under the section titled "Risk Factors" or in other parts of this
Annual Report on Form 10-K. Our historical results are not necessarily
indicative of the results that may be expected for any period in the future.

A discussion regarding our financial condition and results of operations for the
fiscal year ended March 31, 2022 compared to the fiscal year ended March 31,
2021 is presented below. A discussion regarding our financial condition and
results of operations for the fiscal year ended March 31, 2021 compared to the
fiscal year ended March 31, 2020 can be found in "Management's Discussion and
Analysis of Financial Condition and Results of Operations" in our Final
Prospectus dated June 23, 2021, filed with the SEC pursuant to Rule 424(b) under
the Securities Act on June 25, 2021.

Overview



We are the leading digital platform for U.S. medical professionals, as measured
by the number of U.S. physician members. Our members include more than 80% of
physicians across all 50 states and every medical specialty.

Our mission is to help every physician be more productive and provide better
care for their patients. We are physicians-first, putting technology to work for
doctors instead of the other way around. That guiding principle has enabled
Doximity to become an essential and trusted professional platform for
physicians. Our cloud-based platform provides our members with tools
specifically built for medical professionals, enabling them to collaborate with
their colleagues, securely coordinate patient care, conduct virtual patient
visits, stay up-to-date with the latest medical news and research, and manage
their careers. Doximity membership is free for physicians. Our
revenue-generating customers, primarily pharmaceutical manufacturers and
healthcare systems, have access to a suite of commercial solutions that benefit
from broad physician usage.

At the core of our platform is the largest medical professional network in the
nation, which creates proximity within our community of doctors and hundreds of
thousands of other medical professionals. Verified members can search and
connect with colleagues and specialists, which allows them to better coordinate
patient care and streamline referrals. Our newsfeed addresses the ever
increasing sub-specialization of medical expertise and volume of medical
research by delivering news and information that is relevant to each physician's
clinical practice. We also support physicians in their day-to-day practice of
medicine with mobile-friendly and easy-to-use clinical workflow tools such as
voice and video dialer, secure messaging, and digital faxing.

Our business model has delivered high revenue growth at scale, while increasing
profitability. For the fiscal years ended March 31, 2022, 2021 and 2020, we
recognized revenue of $343.5 million, $206.9 million, and $116.4 million,
respectively, representing year-over-year growth rates of 66% and 78%,
respectively. Our net income was $154.8 million, $50.2 million, and $29.7
million for the fiscal years ended March 31, 2022, 2021, and 2020, respectively.
For the fiscal years ended March 31, 2022, 2021 and 2020, we generated adjusted
EBITDA of $150.3 million, $64.8 million, and $26.6 million, respectively. We
have accomplished this while focusing on our core mission to help every
physician be more productive and provide better care for their patients.

Impact of COVID-19



The COVID-19 pandemic has had, and continues to have, a significant impact on
the U.S. economy and the markets in which we operate. Doximity has been
privileged to play an important role in supporting physicians, medical
professionals, and health systems nationwide during this time. Our business has
performed strongly, demonstrating the value and effectiveness of our platform to
both our members and customers. While certain of the COVID-19 pandemic-related
trends underlying our positive performance may not continue after the pandemic
eases, we believe that certain key underlying trends have been accelerated and
will persist long after the pandemic ends.

We continue to closely monitor the impact of the COVID-19 pandemic on all
aspects of our business. While the COVID-19 pandemic has not had a material
adverse impact on our financial condition and results of operations to date, the
extent to which the outbreak of the COVID-19 pandemic or any other pandemic,
epidemic, or infectious diseases will impact our business, results of operations
and financial condition in the future is still unknown and will depend on future
developments, which are highly uncertain and cannot be predicted.

                                       47

--------------------------------------------------------------------------------

For additional information, see "Risk Factors-Risks Related to Our Business-The
COVID-19 pandemic and any other future pandemic, epidemic, or outbreak of an
infectious disease may adversely affect our business, financial condition, and
results of operations."

Key Business and Financial Metrics

We monitor a number of key business and financial metrics to assess the health and success of our business, including:



Customers with Trailing 12-Month Subscription Revenue Greater than $100,000. The
number of customers with trailing 12-month, or TTM, product revenue greater than
$100,000 is calculated by counting the number of customers that contributed more
than $100,000 in subscription revenue in the TTM period. The number of customers
with TTM subscription-based revenue of at least $100,000 is a key indicator of
the scale of our business. Our customer count is subject to adjustments for
acquisitions, consolidations, spin-offs, and other market activity.

The number of customers with at least $100,000 of revenue has grown steadily in
recent years as we have engaged new customers and expanded within existing ones.
This cohort of customers accounted for approximately 88% of our revenue in
fiscal 2022.

                                                                   March 31,
                                                          2022         2021      2020

Number of customers with at least $100,000 of revenue 265 200 141




Net Revenue Retention Rate. Net revenue retention rate is calculated by taking
the TTM subscription-based revenue from our customers that had revenue in the
prior TTM period and dividing that by the total subscription-based revenue for
the prior TTM period. Our net revenue retention rate compares our subscription
revenue from the same set of customers across comparable periods and reflects
customer renewals, expansion, contraction, and churn.

                                         March 31,
                                2022        2021       2020
Net revenue retention rate       157  %     153  %     130  %


Non-GAAP Financial Measures

We use adjusted EBITDA and free cash flow to measure our performance and identify trends, to formulate financial projections, and to make strategic decisions.

Adjusted EBITDA



We define adjusted EBITDA as net income before interest, income taxes,
depreciation and amortization, and as further adjusted for acquisition and other
related expenses, stock-based compensation expense, and other income, net. Net
income margin represents net income as a percentage of revenue and adjusted
EBITDA margin represents adjusted EBITDA as a percentage of revenue.

Adjusted EBITDA is a key measure we use to assess our financial performance and
is also used for internal planning and forecasting purposes. We believe adjusted
EBITDA is helpful to investors, analysts, and other interested parties because
it can assist in providing a more consistent and comparable overview of our
operations across our historical financial periods.

Adjusted EBITDA and adjusted EBITDA margin are non-GAAP measures and are
presented for supplemental informational purposes only and should not be
considered as alternatives or substitutes to the financial information presented
in accordance with GAAP. These measures have certain limitations in that they do
not include the impact of certain expenses that are reflected in our
consolidated statement of operations that are necessary to run our business.
Other companies, including other companies in our industry, may not use these
measures or may calculate these measures differently than as presented in this
Annual Report on Form 10-K, limiting their usefulness as comparative measures.

Adjusted EBITDA and adjusted EBITDA margin increased year-over-year primarily due to higher net income as a result of increased subscription revenue.


                                       48

--------------------------------------------------------------------------------

A reconciliation of net income to adjusted EBITDA and adjusted EBITDA margin is set forth below along with net income margin:


                                                       Fiscal Year Ended March 31,
                                                   2022              2021            2020
                                                               (unaudited)
                                                    (in thousands, except percentages)
Net income                                   $    154,783        $  50,210       $  29,737
Adjusted to exclude the following:
Acquisition and other related expenses                254              496  

1,158


Stock-based compensation                           31,442            7,252  

2,353


Depreciation and amortization                       5,040            3,702             900
Provision for (benefit from) income taxes         (40,778)           7,559          (6,223)
Other income, net                                    (469)          (4,466)         (1,351)
Adjusted EBITDA                              $    150,272        $  64,753       $  26,574
Revenue                                      $    343,548        $ 206,897       $ 116,388
Net income margin                                      45   %           24  %           26  %
Adjusted EBITDA margin                                 44   %           31  %           23  %


Free Cash Flow

Free cash flow is a key performance measure that our management uses to assess
our overall performance. We consider free cash flow to be a liquidity measure
that provides useful information to management and investors about the amount of
cash generated by our business that can be used for strategic opportunities,
including investing in our business, making strategic acquisitions, and
strengthening our financial position.

We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.



The following table presents a reconciliation of our free cash flow to the most
comparable GAAP measure, net cash provided by operating activities, for each of
the periods indicated:

                                                         Fiscal Year Ended March 31,
                                                      2022           2021           2020
                                                                (in thousands)

Net cash provided by operating activities $ 126,575 $ 82,973

$ 26,199


     Purchases of property and equipment              (1,912)          

(245) (285)

Internal-use software development costs (3,785) (4,365) (3,959)


     Free cash flow                               $  120,878      $  78,363

$ 21,955

Other cash flow components:

Net cash used in investing activities $ (640,574) $ (70,417) $ (13,095)

Net cash provided by financing activities $ 560,415 $ 5,407

$ 1,719




Although we believe free cash flow is a useful indicator of business
performance, free cash flow is presented for supplemental informational purposes
only and should not be considered a substitute for financial information
presented in accordance with GAAP. Free cash flow has limitations as an
analytical tool, and it should not be considered in isolation or as a substitute
for analysis of other GAAP financial measures, such as cash provided by
operating activities. Some of the limitations of free cash flow are that it may
not properly reflect capital commitments to creators that need to be paid in the
future or future contractual commitments that have not been realized in the
current period. Our free cash flow may not be comparable to similarly titled
measures of other companies because they may not calculate free cash flow in the
same manner as we calculate the measure, limiting its usefulness as a
comparative measure.

Components of Results of Operations

Revenue



Marketing Solutions. Our customers purchase a subscription to Marketing
Solutions, either directly or through marketing agencies, for the ability to
share tailored content on the Doximity platform via a variety of modules for
defined time
                                       49

--------------------------------------------------------------------------------

periods. We generally bill customers a portion of the contract upon contract
execution and then bill throughout the remainder of the contract based on
various time-based milestones. Generally, we bill in advance of revenue
recognition and record unbilled revenue on the consolidated balance sheets
within prepaid expenses and other current assets when revenue is recognized in
advance of billings. Subscriptions to Marketing Solutions include the following
contractual arrangements:

•Subscriptions for specific modules delivered on a monthly basis to a consistent
number of targeted Doximity members during the subscription period. Pricing is
based on the number and composition of the targeted Doximity members and on the
specific modules purchased.

•Integrated subscriptions for a fixed subscription fee that are not tied to a
single module, allowing customers to utilize any combination of modules during
the subscription period.

For these subscription-based contractual arrangements, we recognize revenue over time as control of the service is transferred to the customer.



Hiring Solutions. We provide customers access to our platform which enables them
to post job openings or deliver a fixed number of monthly messages to our
network of medical professionals. We bill annually or quarterly ahead of the
service period, or at the beginning of each month of service, and recognize
revenue ratably over the contractual term.

Through our acquisition of Curative Talent, completed in fiscal 2021, we also
generate revenue from temporary and permanent medical recruiting services which
we charge on an hourly-fee and placement-fee basis, respectively. Revenue for
temporary placement services is recognized net of third-party contractor fees.
For the fiscal year ended March 31, 2022, the revenue from temporary and
permanent medical recruiting services was not significant to our total revenue.

Cost of Revenue



Cost of revenue is primarily comprised of expenses related to cloud hosting,
personnel-related expenses for our customer success team, costs for third-party
platform access, software services and contractors, and other services used in
connection with the delivery and support of our platform. Our cost of revenue
also includes the amortization of internal-use software development costs and
deferred contract costs, editorial and other content-related expenses, and
allocated overhead. Cost of revenue is also driven by the growth of our member
network and utilization of our telehealth tools. We intend to continue to invest
additional resources in our cloud infrastructure and our customer support
organizations to support the growth of our business and expect these expenses to
increase on an absolute dollar basis.

Gross Profit and Gross Margin



Gross profit is total revenue less total cost of revenue. Gross margin is gross
profit expressed as a percentage of total revenue. Gross profit and gross margin
has been and will continue to be affected by a number of factors, including the
timing of our acquisition of new customers and sales of additional solutions to
our existing customers, the timing and extent of our investments in our
operations, cloud hosting costs, growth in our customer success team, and the
timing of amortization of internal-use software development costs. We expect our
gross margin to remain relatively steady over the near term, although our
quarterly gross margin is expected to fluctuate from period to period depending
on the interplay of these and other factors.

Operating Expenses

Our operating expenses consist of sales and marketing, research and development, and general and administrative expenses.

Research and Development



Research and development expense is primarily comprised of personnel-related
expenses associated with our engineering and product teams who are responsible
for building new products and improving existing products. Research and
development expense also includes costs for third-party services and
contractors, information technology and software-related costs, and allocated
overhead. Other than internal-use software development costs that qualify for
capitalization, research and development costs are expensed as incurred. We
expect research and development expenses will increase on an absolute dollar
basis as we continue to grow our platform and product offerings.

Sales and Marketing



Sales and marketing expense is primarily comprised of personnel-related
expenses, sales commissions, travel, and other event expenses. Sales and
marketing expense also includes costs for third-party services and contractors,
information technology and software-related costs, and allocated overhead. We
capitalize the sales commissions that are considered to be

                                       50

--------------------------------------------------------------------------------

incremental and recoverable costs of obtaining a contract with a customer. These
sales commissions are amortized over the period of benefit. We expect sales and
marketing expense to increase and to be our largest expense on an absolute
basis.

General and Administrative



General and administrative expense is primarily comprised of personnel-related
expenses associated with our executive, finance, legal, human resources,
information technology, and facilities employees. General and administrative
expense includes fees for third-party legal and accounting services, recruitment
fees, information technology and software-related costs, and allocated overhead.
We expect that general and administrative expense will increase on an absolute
dollar basis as we incur compliance costs associated with being a
publicly-traded company, including legal, audit, and consulting fees.

Other Income, Net

Other income, net consists primarily of administrative fees and penalties and interest income earned on our cash equivalents and marketable securities.

Provision for (Benefit from) Income Taxes



Provision for (benefit from) income taxes consists primarily of income taxes in
U.S federal, state, and local jurisdictions in which we conduct business. We
continue to maintain a valuation allowance related to specific net deferred tax
assets where it is not more likely than not that the deferred tax assets will be
realized, which includes California research and development credits and capital
loss carryforwards.

Results of Operations

The following tables set forth our consolidated results of operations data and such data as a percentage of revenue for the periods presented.



                                                         Fiscal Year Ended March 31,
                                                     2022           2021           2020
                                                               (in thousands)
     Revenue                                      $ 343,548      $ 206,897      $ 116,388
     Cost of revenue(1)                              39,787         31,196         14,900
     Gross profit                                   303,761        175,701        101,488
     Operating expenses:
     Research and development(1)                     62,350         43,873         32,435
     Sales and marketing(1)                          92,129         62,033         39,448
     General and administrative(1)                   35,746         16,492          7,442
     Total operating expenses                       190,225        122,398         79,325
     Income from operations                         113,536         53,303         22,163
     Other income, net                                  469          4,466          1,351
     Income before income taxes                     114,005         57,769         23,514
     Provision for (benefit from) income taxes      (40,778)         7,559         (6,223)
     Net income                                   $ 154,783      $  50,210      $  29,737

_______________

(1)Costs and expenses include stock-based compensation expenses as follows:


                                                        Fiscal Year Ended March 31,
                                                       2022             2021         2020
                                                               (in thousands)
     Cost of revenue                            $     4,979           $   600      $   173
     Research and development                         7,065             

1,975 710


     Sales and marketing                              8,108             

1,998 847


     General and administrative                      11,290             

2,679 623


     Total stock-based compensation expense     $    31,442           $ 7,252      $ 2,353


                                       51

--------------------------------------------------------------------------------


                                                          Fiscal Year Ended March 31,
                                                          2022                 2021       2020
                                                            (percentage of revenue)
 Revenue                                                            100  %     100  %     100  %
 Cost of revenue                                                     12         15         13
 Gross profit                                                        88         85         87
 Operating expenses:
 Research and development                                            18         21         28
 Sales and marketing                                                 27         30         34
 General and administrative                                          10          8          6
 Total operating expenses                                            55         59         68
 Income from operations                                              33         26         19
 Other income, net                                                    -          2          1
 Income before income taxes                                          33         28         20
 Provision for (benefit from) income taxes                          (12)         4         (6)
 Net income                                                          45  %      24  %      26  %

Comparison of the Years Ended March 31, 2022 and 2021



Revenue

                  Fiscal Year Ended March 31,                   Change
                      2022                  2021             $            %
                            (in thousands, except percentages)
Revenue     $      343,548               $ 206,897      $ 136,651        66  %


Revenue for the fiscal year ended March 31, 2022 increased $136.7 million as
compared to the fiscal year ended 2021. The increase was primarily driven by a
$127.0 million increase in subscription revenue. Of the increase in subscription
revenue, $16.8 million was driven by the addition of new subscription customers1
and $109.0 million was due to the expansion of existing customers. The expansion
of existing customers was primarily driven by average revenue per existing
Marketing Solutions customer increasing by 60% as a result of adding new brands
and service lines, growing existing brands and service lines, and upselling
additional modules. The remaining change in subscription revenue was generated
from Dialer Pro subscriptions for individuals and small practices and other
non-recurring items. Approximately 93% of our revenue for the fiscal year ended
March 31, 2022 was derived from subscription customers. The remaining increase
in revenue was driven by an increase in medical recruiting services.

Cost of revenue, gross profit and gross margin



                        Fiscal Year Ended March 31,                   Change
                        2022                      2021             $            %
                                  (in thousands, except percentages)
Cost of revenue   $      39,787               $  31,196       $   8,591        28  %
Gross profit      $     303,761               $ 175,701       $ 128,060        73  %
Gross margin                 88   %                  85  %


Cost of revenue for the fiscal year ended March 31, 2022 increased $8.6 million
as compared to the fiscal year ended 2021. The increase in cost of revenue was
primarily driven by a $4.2 million increase in personnel-related costs as a
result of headcount growth of 36%, $2.6 million increase in expense from the
U.S. News warrant granted in October 2021, and a $1.8 million increase in
stock-based compensation expense due to headcount growth and an increase in the
weighted-average grant date fair values of our equity grants. In addition, there
was a $1.2 million increase in consulting services and a $1.3 million increase
in amortization of internal-use software development costs. These increases were
partially offset by a $3.0 million decrease in third-party software as a result
of renegotiating pricing terms with vendors combined with a lower volume of
virtual visits as compared to the prior period, when our Dialer tool was
available to all members for free.

Gross margin increased due to our revenue growth and continued efficiency as we scale.

1 We define new subscription customers as revenue generating subscription customers in the current fiscal period who did not contribute any revenue for the same period in the prior fiscal year.


                                       52

--------------------------------------------------------------------------------


Operating Expenses

Research and development

                                  Fiscal Year Ended March 31,                  Change
                                      2022                   2021           $            %
                                           (in thousands, except percentages)
Research and development   $       62,350                 $ 43,873      $ 18,477        42  %


Research and development expense for the fiscal year ended March 31, 2022
increased $18.5 million as compared to the fiscal year ended 2021. The increase
in research and development expense was primarily driven by a $9.8 million
increase in personnel-related costs as a result of headcount growth of
approximately 26%. The increase was also driven by a $5.1 million increase in
stock-based compensation primarily attributable to headcount growth and an
increase in the weighted-average grant date fair values of our equity grants.
The increase was also due to a $2.3 million increase in third-party software
subscription and license costs as a result of headcount growth as well as a $1.1
million increase in employee events and travel-related expenses as we resumed
certain in-person events.

Sales and marketing

                               Fiscal Year Ended March 31,                  Change
                                   2022                   2021           $            %
                                        (in thousands, except percentages)
Sales and marketing     $       92,129                 $ 62,033      $ 30,096        49  %


Sales and marketing expense for the fiscal year ended March 31, 2022 increased
$30.1 million as compared to the fiscal year ended 2021. The overall increase in
sales and marketing expense was due to the growth in our business, specifically
driven by a $10.7 million increase in personnel-related costs due to headcount
growth of 23% as well as a $5.4 million increase in incentive compensation due
to increased sales activity. The increase was also driven by a $6.1 million
increase in stock-based compensation mainly due to headcount growth and an
increase in the weighted-average grant date fair values of our equity grants.
Additionally, there was a $2.5 million increase in deferred contract costs
amortization due to higher sales volume, a $2.2 million increase for in-person
trade shows and conferences, advertising and other marketing expenses, and a
$1.4 million increase in employee events and travel-related expenses as we
resumed certain in-person events.

General and administrative

                                     Fiscal Year Ended March 31,                  Change
                                         2022                   2021           $            %
                                              (in thousands, except percentages)
General and administrative    $       35,746                 $ 16,492      $ 19,254       117  %


General and administrative expense for the fiscal year ended March 31, 2022
increased $19.3 million as compared to the fiscal year ended 2021. The increase
in general and administrative expense was primarily driven by an $8.6 million
increase in stock-based compensation, of which $5.3 million related to the
increase in headcount and the weighted-average grant date fair values of our
equity awards and $3.3 million was due to performance grants where the
performance conditions were met or became probable of achievement during fiscal
2022. In addition, there was a $2.8 million increase in personnel-related costs
due to headcount growth of approximately 48%, a $3.1 million increase in
insurance expense, and a $3.1 million increase in accounting, legal, and other
services as we incurred additional expenses as a result of becoming a public
company.

Other income, net

                            Fiscal Year Ended March 31,                   Change
                                 2022                   2021           $            %
                                     (in thousands, except percentages)
Other income, net    $        469                     $ 4,466      $ (3,997)      (89) %


Other income, net for the fiscal year ended March 31, 2022 decreased $4.0
million compared to the fiscal year ended 2021. The decrease was primarily
driven by a $4.7 million non-recurring gain that was recognized in October 2020
upon the sale of a portion of the Curative Talent business, offset by a $0.6
million increase in interest income due to our increased investment in
marketable securities.

                                       53

--------------------------------------------------------------------------------

Provision for (benefit from) income taxes



                                              Fiscal Year Ended March 31,                     Change
                                                2022               2021                $                  %
                                                             (in thousands, except percentages)
Provision for (benefit from) income taxes   $  (40,778)         $  7,559          $ (48,337)                   NM


For the fiscal year ended March 31, 2022, we had an income tax benefit of $40.8
million compared to a provision of $7.6 million for the fiscal year ended 2021.
This change was primarily driven by excess tax benefit on stock option exercise
and disqualifying disposition activities following our initial public offering
in June 2021.

___________________

NM: Percentage not meaningful.

Liquidity and Capital Resources



Since inception, we have financed operations primarily through proceeds received
from sales of equity securities and payments received from our customers. As of
March 31, 2022, our principal sources of liquidity were cash and cash
equivalents and marketable securities of $798.1 million. Our marketable
securities consist of U.S. government and agency securities, corporate notes and
bonds, commercial paper, asset-backed securities, and sovereign bonds.

In June 2021, we completed our IPO, in which we issued and sold 22,505,750 shares of our Class A common stock at $26.00 per share, including 3,495,000 shares issued upon the exercise of the underwriters' option to purchase additional shares. We received proceeds of $548.5 million after deducting underwriting discounts and commissions as well as deferred offering costs.

We believe that our existing cash and cash equivalents and marketable securities will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months.



Our future capital requirements will depend on many factors, including our
revenue growth rate, the timing and the amount of cash received from customers,
the expansion of sales and marketing activities, and the timing and extent of
spending to support research and development efforts. Further, we may in the
future enter into arrangements to acquire or invest in businesses and
technologies. We may be required to seek additional equity or debt financing. In
the event that additional financing is required from outside sources, we may not
be able to raise it on terms acceptable to us or at all. If we are unable to
raise additional capital when desired, our business, financial condition, and
results of operations could be adversely affected.

For further details regarding our cash requirements from noncancelable operating
lease obligations and other contractual commitments, see Note 13-Commitments and
Contingencies included in Part II, Item 8 of this Annual Report on Form 10-K.

Cash Flows

                                                      Fiscal Year Ended March 31,
                                                          2022                  2021
                                                             (in thousands)
   Net cash provided by operating activities    $       126,575

$ 82,973


   Net cash used in investing activities        $      (640,574)

$ (70,417)


   Net cash provided by financing activities    $       560,415

$ 5,407

Net cash provided by operating activities



Cash provided by operating activities was $126.6 million for the fiscal year
ended March 31, 2022. This consisted of net income of $154.8 million, adjusted
for non-cash items of $12.1 million and a net decrease in operating assets and
liabilities of $40.3 million. Non-cash items primarily consisted of stock-based
compensation expense of $31.4 million, amortization of deferred contract costs
of $9.8 million, depreciation and amortization expense of $5.0 million,
amortization of the premium on marketable securities of $4.3 million, offset by
a negative non-cash adjustment for deferred tax benefit of $41.2 million. The
net decrease in operating assets and liabilities was driven by a $31.0 million
increase in accounts receivable due to the growth of our business and the timing
of collections, a $9.6 million increase in deferred contract costs due to
increased sales activity, and a $9.1 million increase in prepaid expenses and
other assets. These decreases were partially offset by an increase of $8.7
million in accounts payable, accrued expenses and other liabilities, which was
primarily a result of increased accrued payroll, bonus,

                                       54

--------------------------------------------------------------------------------

and related expenses due to increased headcount and timing of payments and increased rebate liabilities due to higher sales combined with the timing of payments.



Cash provided by operating activities was $83.0 million for the fiscal year
ended March 31, 2021. This consisted of net income of $50.2 million, adjusted
for non-cash items of $21.2 million and a net increase in operating assets and
liabilities of $11.6 million. Non-cash items primarily consisted of stock-based
compensation expense of $7.3 million, amortization of deferred contract costs of
$6.9 million, deferred income tax expense of $5.0 million, and depreciation and
amortization expense of $3.7 million, partially offset by a $4.7 million gain
due to the sale of a portion of the Curative Talent business. The net increase
in operating assets and liabilities was primarily driven by an increase of $38.6
million in deferred revenue due to the addition of new customers and expansion
from existing customers combined with the timing of customer billings and an
increase of $7.3 million in accounts payable, accrued expenses and other
liabilities, which was primarily a result of increased accrued incentive
compensation due to higher sales and timing of payments and increased accrued
payroll, bonus, and related expenses due to increased headcount and timing of
payments. These increases were partially offset by an increase of $20.5 million
in accounts receivable due to the growth of our business and the timing of
collections and an increase of $9.4 million in deferred contract costs due to
increased sales activity.

Net cash used in investing activities



Cash used in investing activities was $640.6 million for the fiscal year ended
March 31, 2022, which primarily consisted of purchases of marketable securities
of $1.3 billion, partially offset by proceeds from the sale of marketable
securities of $633.8 million, proceeds from the maturities of marketable
securities of $47.9 million, and capitalization of internal-use software
development costs of $3.8 million.

Cash used in investing activities was $70.4 million for the fiscal year ended
March 31, 2021, which primarily consisted of purchases of marketable securities
of $78.9 million and cash paid for the acquisition of Curative Talent of $31.7
million, partially offset by proceeds from the maturities of marketable
securities of $40.5 million.

Net cash provided by financing activities



Cash provided by financing activities was $560.4 million for the fiscal year
ended March 31, 2022, which primarily consisted of $553.9 million of proceeds
from the issuance of common stock upon our initial public offering after
deducting underwriting fees and commissions, $12.6 million of net proceeds from
the exercise of stock options, and $1.4 million of proceeds from the issuance of
common stock in connection with the employee stock purchase plan. These proceeds
were partially offset by $4.0 million in payments for deferred offering costs
and $2.7 million in payments from the repurchase and retirement of common stock.

Cash provided by financing activities was $5.4 million for the fiscal year ended
March 31, 2021, which primarily consisted of $8.9 million of net proceeds from
the exercise of stock options, partially offset by $1.5 million in payments for
deferred offering costs and $2.0 million from the repurchase and retirement of
common stock.

Off Balance Sheet Arrangements



We did not have during the periods presented, and we do not currently have, any
off-balance sheet financing arrangements or any relationships with
unconsolidated entities or financial partnerships, including entities sometimes
referred to as structured finance or special purpose entities, that were
established for the purpose of facilitating off-balance sheet arrangements or
other contractually narrow or limited purposes.

Critical Accounting Policies and Estimates



Our consolidated financial statements and the related notes thereto included
elsewhere in this Annual Report on Form 10-K are prepared in accordance with
GAAP. The preparation of our financial statements also requires us to make
estimates and assumptions that affect the amounts stated in the consolidated
financial statements and accompanying notes. We base our estimates and judgments
on historical experience and on various other assumptions that we believe are
reasonable under the circumstances. Actual results could differ significantly
from the estimates made by management. To the extent that there are differences
between our estimates and actual results, our future financial statement
presentation, financial condition, results of operations, and cash flows will be
affected.

We believe that of our significant accounting policies, which are described in
Note 2-Summary of Significant Accounting Policies included in Part II, Item 8 of
this Annual Report on Form 10-K, the following accounting policies involve a
greater degree of judgment and complexity. Accordingly, we believe the below
policies are the most critical to aid in fully understanding and evaluating our
consolidated financial statements.

                                       55

--------------------------------------------------------------------------------

Revenue Recognition



Marketing Solutions customers may purchase a subscription for a specific module
to be used over a defined period of time. These customers may purchase more than
one module with either the same or different subscription periods. Each module
targets a consistent number of Doximity members per month for the duration of
the subscription period. The Company treats each subscription to a specific
module as a distinct performance obligation because each module is capable of
being distinct as the customer can benefit from the subscription to each module
on their own and each subscription can be sold standalone. The subscription to
each module is treated as a series of distinct performance obligations because
it is distinct and substantially the same, satisfied over time, and has the same
measure of progress. The total transaction price is allocated to the individual
module subscriptions, which represent separate performance obligations, based on
the relative standalone selling price. We commence revenue recognition when the
first content for the specific module is launched on the platform for the
initial monthly period and revenue is recognized over time as each subsequent
content period is delivered.

Marketing Solutions customers may also purchase integrated subscriptions for a
fixed subscription fee that are not tied to a single module but allow customers
to utilize any combination of modules during the subscription period subject to
limits on the total number of modules launched in a given period of time, active
at any given time, and members targeted. These represent stand-ready obligations
in that the delivery of the underlying sponsored content is within the control
of the customer and the extent of use in any given period does not diminish the
remaining services. For these integrated campaign subscriptions, we record
revenue ratably over the subscription period commencing with the beginning of
the subscription term.

Stock-Based Compensation

We account for stock-based compensation in accordance with the authoritative
guidance on stock compensation. Under the fair value recognition provisions of
this guidance, stock-based compensation is measured at the grant date based on
the fair value of the award and is recognized as expense, net of estimated
forfeitures, in the statement of operations over the requisite service period,
which is generally the vesting period of the respective award. Forfeitures are
estimated based upon our historical experience and we revise the estimates, if
necessary, in subsequent periods if actual forfeitures differ from initial
estimates.

Determining the grant-date fair value of stock options requires judgment. We
estimate the fair value of restricted stock units, or RSUs, at our stock price
on the grant date. We use the Black-Scholes option-pricing model to determine
the fair value of stock options, warrants, purchase rights under the employee
stock purchase plan, or ESPP. The determination of the grant-date fair value
using the Black-Scholes model is affected by the fair value of our common stock
and assumptions regarding a number of other complex and subjective variables.
These assumptions include the expected term of the award, the expected stock
price volatility over the expected term of the award, the risk-free interest
rate for the expected term of the award, and expected dividends.

Prior to the IPO, when there was no public market for our common stock,
significant judgment was involved in determining the fair value of our common
stock and the expected stock price volatility. Our board of directors considered
numerous objective and subjective factors to determine the fair value of our
common stock at each meeting during which awards were approved. These factors
included, but were not limited to (i) contemporaneous third-party valuations of
common stock; (ii) the rights and preferences of our preferred stock relative to
common stock; (iii) the lack of marketability of common stock; (iv) developments
in the business; and (v) the likelihood of achieving a liquidity event, such as
an IPO or sale of the Company, given prevailing market conditions. The expected
volatility was determined using the historical volatilities of several publicly
listed peer companies over a period equivalent to the expected term of the
awards. We have not granted stock options to employees subsequent to the IPO.

Business Combinations



We allocate the purchase price of acquired companies to tangible and intangible
assets acquired and liabilities assumed based upon their estimated fair values
at the acquisition date. The purchase price allocation process requires
management to make significant estimates and assumptions with respect to the
valuation of intangible assets. Examples of critical estimates in valuing
certain of the intangible assets we have acquired or may acquire in the future
include but are not limited to future expected cash flows, future revenue
growth, margins, customer retention rates, technology life, royalty rates,
expected use of acquired assets, and discount rates. These factors are also
considered in determining the useful life of the acquired intangible assets.
These estimates are based in part on historical experience, market conditions
and information obtained from management of the acquired companies and are
inherently uncertain. Goodwill represents the future economic benefits arising
from other assets acquired in a business combination that are not individually
identified and separately recorded.

                                       56

--------------------------------------------------------------------------------

Recent Accounting Pronouncements

Refer to Note 2-Summary of Significant Accounting Policies included in Part II, Item 8 of this Annual Report on Form 10-K for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted.

Jumpstart Our Business Startups Act of 2012



We are an emerging growth company, as defined in the JOBS Act. The JOBS Act
provides that an emerging growth company can take advantage of an extended
transition period for complying with new or revised accounting standards. This
provision allows an emerging growth company to delay the adoption of some
accounting standards until those standards would otherwise apply to private
companies. We have elected to use the extended transition period under the JOBS
Act for the adoption of certain accounting standards until the earlier of the
date we (i) are no longer an emerging growth company or (ii) affirmatively and
irrevocably opt out of the extended transition period provided in the JOBS Act.
As a result, our financial statements may not be comparable to companies that
comply with new or revised accounting pronouncements as of public company
effective dates.

© Edgar Online, source Glimpses